A dynamic web-based decision aid to improve informed choice in organised breast cancer screening. A pragmatic randomised trial in Italy.


Journal

British journal of cancer
ISSN: 1532-1827
Titre abrégé: Br J Cancer
Pays: England
ID NLM: 0370635

Informations de publication

Date de publication:
09 2020
Historique:
received: 24 12 2019
accepted: 26 05 2020
revised: 06 05 2020
pubmed: 18 6 2020
medline: 1 4 2021
entrez: 18 6 2020
Statut: ppublish

Résumé

Improving the quality of information and communication is a priority in organised breast cancer screening and an ethical duty. Programmes must offer the information each woman is looking for, promoting informed decision-making. This study aimed to develop and evaluate a web-based dynamic decision aid (DA). A pragmatic randomised trial carried out in six regional organised screening programmes recruited women at the first invitation receiving DA or a web-based standard brochure (SB). The primary outcome was informed choice measured on knowledge, attitudes, and intentions. Follow-up period: 7-10 days. Secondary outcomes included participation rate, satisfaction, decisional conflict, and acceptability of DA. Two thousand one hundred and nineteen women were randomised and 1001 completed the study. Respectively, 43.9% and 36.9% in the DA and SB reached the informed choice. The DA gave a 13-point higher proportion of women aware about overdiagnosis compared to SB (38.3% versus 25.2%, p < 0.0001). The percentage of women attending screening was the same: 84% versus 83%. Decisional conflict was significantly lower in the DA group (14.4%) than in the SB group (19.3%). DA increases informed choice. Complete information including the pros, cons, controversies, and overdiagnosis-overtreatment issues boost a woman's knowledge without reducing the rate of actual screening participation. ClinicalTrials.gov number NCT03097653.

Sections du résumé

BACKGROUND
Improving the quality of information and communication is a priority in organised breast cancer screening and an ethical duty. Programmes must offer the information each woman is looking for, promoting informed decision-making. This study aimed to develop and evaluate a web-based dynamic decision aid (DA).
METHODS
A pragmatic randomised trial carried out in six regional organised screening programmes recruited women at the first invitation receiving DA or a web-based standard brochure (SB). The primary outcome was informed choice measured on knowledge, attitudes, and intentions. Follow-up period: 7-10 days. Secondary outcomes included participation rate, satisfaction, decisional conflict, and acceptability of DA.
RESULTS
Two thousand one hundred and nineteen women were randomised and 1001 completed the study. Respectively, 43.9% and 36.9% in the DA and SB reached the informed choice. The DA gave a 13-point higher proportion of women aware about overdiagnosis compared to SB (38.3% versus 25.2%, p < 0.0001). The percentage of women attending screening was the same: 84% versus 83%. Decisional conflict was significantly lower in the DA group (14.4%) than in the SB group (19.3%).
CONCLUSION
DA increases informed choice. Complete information including the pros, cons, controversies, and overdiagnosis-overtreatment issues boost a woman's knowledge without reducing the rate of actual screening participation.
CLINICAL TRIAL REGISTRATION
ClinicalTrials.gov number NCT03097653.

Identifiants

pubmed: 32546834
doi: 10.1038/s41416-020-0935-2
pii: 10.1038/s41416-020-0935-2
pmc: PMC7462858
doi:

Banques de données

ClinicalTrials.gov
['NCT03097653']

Types de publication

Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

714-721

Commentaires et corrections

Type : ErratumIn

Références

Ferlay, J., Colombet, M., Soerjomataram, I., Dyba, T., Randi, G., Bettio, M. et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries and 25 major cancers in 2018. Eur. J. Cancer 103, 356–387 (2018).
doi: 10.1016/j.ejca.2018.07.005
Armaroli, P., Villain, P., Suonio, E., Almonte, M., Anttila, A., Atkin, W. S. et al. European Code against Cancer, 4th Edition: cancer screening. Cancer Epidemiol. 39(Suppl 1), S139–S152 (2015).
doi: 10.1016/j.canep.2015.10.021
IARC. When should I participate in breast cancer screening? https://cancer-code-europe.iarc.fr/index.php/en/ecac-12-ways/screening-recommandation/breast-cancer-screening/229-participate-in-breast-cancer-screening (2016). Accessed 1 Apr 2020.
Basu, P., Ponti, A., Anttila, A., Ronco, G., Senore, C., Vale, D. B. et al. Status of implementation and organization of cancer screening in The European Union Member States-summary results from the second European screening report. Int. J. Cancer 142, 44–56 (2018).
doi: 10.1002/ijc.31043
Osservatorio Nazionale Screening. Lo screening mammografico. https://www.osservatorionazionalescreening.it/content/lo-screening-mammografico (2018) Accessed 1 Apr 2020.
Bucchi, L., Ravaioli, A., Baldacchini, F., Giuliani, O., Mancini, S., Vattiato, R. et al. Annual mammography at age 45-49 years and biennial mammography at age 50-69 years: comparing performance measures in an organised screening setting. Eur. Radiol. 29, 5517–5527 (2019).
doi: 10.1007/s00330-019-06050-w
European Union. Council recommendation of 2 December 2003 on cancer screening. L 327/34. https://ec.europa.eu/jrc/sites/jrcsh/files/2_December_2003%20cancer%20screening.pdf (2003). Accessed 1 Apr 2020.
Gotzsche, P. C., Hartling, O. J., Nielsen, M., Brodersen, J. & Jorgensen, K. J. Breast screening: the facts-or maybe not. BMJ 338, b86 (2009).
doi: 10.1136/bmj.b86
Jorgensen, K. J. & Gotzsche, P. C. Presentation on websites of possible benefits and harms from screening for breast cancer: cross sectional study. BMJ 328, 148 (2004).
doi: 10.1136/bmj.328.7432.148
Slaytor, E. K. & Ward, J. E. How risks of breast cancer and benefits of screening are communicated to women: analysis of 58 pamphlets. BMJ 317, 263–264 (1998).
doi: 10.1136/bmj.317.7153.263
Domenighetti, G., D’Avanzo, B., Egger, M., Berrino, F., Perneger, T., Mosconi, P. et al. Women’s perception of the benefits of mammography screening: population-based survey in four countries. Int. J. Epidemiol. 32, 816–821 (2003).
doi: 10.1093/ije/dyg257
Domenighetti, G., Grilli, R. & Maggi, J. R. Does provision of an evidence-based information change public willingness to accept screening tests? Health Expect. 3, 145–150 (2000).
doi: 10.1046/j.1369-6513.2000.00081.x
Olsen, O. & Gotzsche, P. C. Screening for breast cancer with mammography. Cochrane Database Syst. Rev. CD001877 (2001).
Paci, E. Summary of the evidence of breast cancer service screening outcomes in Europe and first estimate of the benefit and harm balance sheet. J. Med. Screen. 19(Suppl 1), 5–13 (2012).
doi: 10.1258/jms.2012.012077
Independent UK Panel on Breast Cancer Screening. The benefits and harms of breast cancer screening: an independent review. Lancet 380, 1778–1786 (2012).
Barratt, A., Jorgensen, K. J. & Autier, P. Reform of the national screening mammography program in France. JAMA Intern. Med. 178, 177–178 (2018).
doi: 10.1001/jamainternmed.2017.5836
Lauby-Secretan, B., Scoccianti, C., Loomis, D., Benbrahim-Tallaa, L., Bouvard, V., Bianchini, F. et al. Breast-cancer screening-viewpoint of the IARC Working Group. N. Engl. J. Med. 372, 2353–2358 (2015).
doi: 10.1056/NEJMsr1504363
European Commission. European guidelines on breast cancer screening and diagnosis. https://ecibc.jrc.ec.europa.eu/recommendations/details/Professional/decisionaid/decisionaid (2020) Accessed 1 Apr 2020.
Gotzsche, P. C. & Jorgensen, K. J. Screening for breast cancer with mammography. Cochrane Database Syst. Rev. CD001877 (2013).
Stacey, D., Legare, F., Lewis, K., Barry, M. J., Bennett, C. L., Eden, K. B. et al. Decision aids for people facing health treatment or screening decisions. Cochrane Database Syst. Rev. 4, CD001431 (2017).
pubmed: 28402085
Roberto, A., Colombo, C., Candiani, G., Giordano, L., Mantellini, P., Paci, E. et al. Personalised informed choice on evidence and controversy on mammography screening: study protocol for a randomized controlled trial. BMC Cancer 17, 429 (2017).
doi: 10.1186/s12885-017-3428-9
Hersch, J., Barratt, A., Jansen, J., Irwig, L., McGeechan, K., Jacklyn, G. et al. Use of a decision aid including information on overdetection to support informed choice about breast cancer screening: a randomised controlled trial. Lancet 385, 1642–1652 (2015).
doi: 10.1016/S0140-6736(15)60123-4
Mathieu, E., Barratt, A., Davey, H. M., McGeechan, K., Howard, K. & Houssami, N. Informed choice in mammography screening: a randomized trial of a decision aid for 70-year-old women. Arch. Intern. Med. 167, 2039–2046 (2007).
doi: 10.1001/archinte.167.19.2039
Mathieu, E., Barratt, A. L., McGeechan, K., Davey, H. M., Howard, K. & Houssami, N. Helping women make choices about mammography screening: an online randomized trial of a decision aid for 40-year-old women. Patient Educ. Couns. 81, 63–72 (2010).
doi: 10.1016/j.pec.2010.01.001
Marmot, M. G., Altman, D. G., Cameron, D. A., Dewar, J. A., Thompson, S. G. & Wilcox, M. The benefits and harms of breast cancer screening: an independent review. Br. J. Cancer 108, 2205–2240 (2013).
doi: 10.1038/bjc.2013.177
Elwyn, G., O’Connor, A. M., Bennett, C., Newcombe, R. G., Politi, M., Durand, M.-A. et al. Assessing the quality of decision support technologies using the International Patient Decision Aid Standards instrument (IPDASi). PLoS ONE 4, e4705 (2009).
doi: 10.1371/journal.pone.0004705
Marteau, T. M., Dormandy, E. & Michie, S. A measure of informed choice. Health Expect. 4, 99–108 (2001).
doi: 10.1046/j.1369-6513.2001.00140.x
Legare, F., Kearing, S., Clay, K., Gagnon, S., D’Amours, D., Rousseau, M. et al. Are you SURE?: assessing patient decisional conflict with a 4-item screening test. Can. Fam. Physician 56, e308–e314 (2010).
pubmed: 20705870 pmcid: 2920798
Ghanouni, A., Meisel, S. F., Renzi, C., Wardle, J. & Waller, J. Survey of public definitions of the term “overdiagnosis” in the UK. BMJ Open 6, e010723 (2016).
doi: 10.1136/bmjopen-2015-010723
Moynihan, R., Nickel, B., Hersch, J., Doust, J., Barratt, A., Beller, E. et al. What do you think overdiagnosis means? A qualitative analysis of responses from a national community survey of Australians. BMJ Open 5, e007436 (2015).
doi: 10.1136/bmjopen-2014-007436
Perez-Lacasta, M. J., Martinez-Alonso, M., Garcia, M., Sala, M., Perestelo-Perez, L., Vidal, C. et al. Effect of information about the benefits and harms of mammography on women’s decision making: the InforMa randomised controlled trial. PLoS ONE 14, e0214057 (2019).
doi: 10.1371/journal.pone.0214057
Hoffmann, T. C. & Del Mar, C. Patients’ expectations of the benefits and harms of treatments, screening, and tests: a systematic review. JAMA Intern. Med. 175, 274–286 (2015).
doi: 10.1001/jamainternmed.2014.6016
Martinez-Alonso, M., Carles-Lavila, M., Perez-Lacasta, M. J., Pons-Rodriguez, A., Garcia, M. & Rue, M. Assessment of the effects of decision aids about breast cancer screening: a systematic review and meta-analysis. BMJ Open 7, e016894 (2017).
doi: 10.1136/bmjopen-2017-016894
Reder, M. & Kolip, P. Does a decision aid improve informed choice in mammography screening? Results from a randomised controlled trial. PLoS ONE 12, e0189148 (2017).
doi: 10.1371/journal.pone.0189148
Burnside, E. S., Sickles, E. A. & Duffy, S. W. A pragmatic approach to determine components of optimal screening mammography practice. JAMA 315, 1951–1953 (2016).
doi: 10.1001/jama.2016.4530
Sunstein, C. R. Choosing not to choose. Duke Law J. 64, 1–52 (2014).
pubmed: 25330554

Auteurs

Anna Roberto (A)

Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milano, Italy.

Cinzia Colombo (C)

Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milano, Italy.

Giulia Candiani (G)

Zadig, Agenzia di Editoria Scientifica, Milano, Italy.

Roberto Satolli (R)

Zadig, Agenzia di Editoria Scientifica, Milano, Italy.

Livia Giordano (L)

SSD Epidemiologia e Screening - CPO Piemonte - AOU Città della Salute e della Scienza, Torino, Italy.

Lina Jaramillo (L)

SSD Epidemiologia e Screening - CPO Piemonte - AOU Città della Salute e della Scienza, Torino, Italy.

Roberta Castagno (R)

SSD Epidemiologia e Screening - CPO Piemonte - AOU Città della Salute e della Scienza, Torino, Italy.

Paola Mantellini (P)

SC Screening e Prevenzione Secondaria, Istituto per lo Studio, la Prevenzione e la Rete Oncologica - ISPRO, Firenze, Italy.

Patrizia Falini (P)

SC Screening e Prevenzione Secondaria, Istituto per lo Studio, la Prevenzione e la Rete Oncologica - ISPRO, Firenze, Italy.

Eva Carnesciali (E)

SC Screening e Prevenzione Secondaria, Istituto per lo Studio, la Prevenzione e la Rete Oncologica - ISPRO, Firenze, Italy.

Mario Valenza (M)

UO Centro Gestionale Screening, ASP di Palermo, Palermo, Italy.

Liliana Costa (L)

U.O.S. Screening Mammografico, ASP di Palermo, Palermo, Italy.

Cinzia Campari (C)

S.S. Screening Oncologici - Azienda Unità Sanitaria Locale - IRCCS di Reggio Emilia, Reggio Emilia, Italy.

Stefania Caroli (S)

S.S. Screening Oncologici - Azienda Unità Sanitaria Locale - IRCCS di Reggio Emilia, Reggio Emilia, Italy.

Roberto Cosimo Faggiano (RC)

S.S. Screening Oncologici - Azienda Unità Sanitaria Locale - IRCCS di Reggio Emilia, Reggio Emilia, Italy.

Lorenzo Orione (L)

Centro Screening Cuneo, ASL CN1, Cuneo, Italy.

Bruna Belmessieri (B)

Centro Screening Cuneo, ASL CN1, Cuneo, Italy.

Vanda Marchiò (V)

Centro Screening Cuneo, ASL CN1, Cuneo, Italy.

Silvia Deandrea (S)

UOC Medicina Preventiva delle Comunità - Screening, ATS della Città Metropolitana di Milano, Milano, Italy.

Anna Silvestri (A)

UOC Medicina Preventiva delle Comunità - Screening, ATS della Città Metropolitana di Milano, Milano, Italy.

Daniela Luciano (D)

UOC Medicina Preventiva delle Comunità - Screening, ATS della Città Metropolitana di Milano, Milano, Italy.

Eugenio Paci (E)

Lega Italiana per la Lotta contro i Tumori, Sezione Firenze, Italy.

Paola Mosconi (P)

Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milano, Italy. paola.mosconi@marionegri.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH